Bi-Specific Mabs Market Research Report 2026: $21.83 Bn Opportunities, Trends, Competitive Landscape, Strategies, And Forecasts, 2020-2025, 2025-2030F, 2035F

(MENAFN- GlobeNewsWire - Nasdaq) The bi-specific mAbs market is poised for growth due to advancements in gene/cell therapy integration, increased R&D for rare diseases, and precision medicine adoption. The market sees expansion in tumor immunotherapy, multi-target antibodies, and growing collaborations between pharma and biotech firms.

Dublin, May 07, 2026 (GLOBE NEWSWIRE) -- The "Bi-Specific MAbS Market Report 2026" has been added to ResearchAndMarkets's offering.

The bi-specific monoclonal antibodies (mAbs) market is experiencing remarkable growth, projected to expand from $11.64 billion in 2025 to $13.16 billion in 2026, with a compound annual growth rate (CAGR) of 13%. This market expansion can be credited to the approval of initial bi-specific antibody therapies, a rising incidence of hematological cancers, and early adoption of mAbs. Investments in oncology R&D and hospital-based clinical trials further fuel this growth.

Looking ahead, the bi-specific mAbs market is set to accelerate, reaching $21.83 billion by 2030, with a projected CAGR of 13.5%. This surge is driven by advancements in gene and cell therapy integration, expanded bi-specific antibody pipelines, increased R&D funding for rare diseases, growth in precision medicine adoption, and emerging novel delivery platforms. Key trends include the expansion of tumor immunotherapy applications, development of multi-targeted antibodies, and collaborative efforts between pharma and biotech firms.

The escalating prevalence of cancer and chronic diseases propels the demand for bispecific mAbs, designed to target multiple tumor antigens, thereby enhancing treatment efficacy. According to the American Cancer Society's Cancer Facts & Figures 2023 report, 609,820 cancer-related deaths were projected in the USA during the year, highlighting the urgency for effective treatments. Bi-specific mAbs offer promising solutions in treating cancers, infectious diseases, and autoimmune disorders.

Leading market players, such as Roche AG, are pioneering technological innovations like CD20??CD3 T-cell engaging bispecific antibodies, addressing the need for effective, fixed-duration immunotherapies in hematological malignancies. For instance, Roche's Columvi (glofitamab-gxbm), a CD20CD3 bispecific T-cell engager launched in June 2023, exemplifies advancements in providing durable treatment responses with manageable safety profiles in clinical trials.

In a significant strategic move, Johnson & Johnson acquired Proteologix, Inc. for $850 million in June 2024. This acquisition enhances Johnson & Johnson's immunology expertise by integrating promising bi-specific antibodies targeting conditions like atopic dermatitis and asthma.

Prominent companies in this market include F. Hoffmann-La Roche AG, Amgen Inc, Johnson & Johnson, and Kyowa Kirin, among others. Notable regions covered in market reports are Asia-Pacific, North America, and Europe, with North America leading in 2025.

Comprehensive market research reports provide valuable insights into bi-specific mAbs market statistics, segmentation, trends, and opportunities, offering a holistic view of the current and future landscape of this growing industry.

Key Attributes:

Report Attribute	Details
No. of Pages	250
Forecast Period	2026 - 2030
Estimated Market Value (USD) in 2026	$13.16 Billion
Forecasted Market Value (USD) by 2030	$21.83 Billion
Compound Annual Growth Rate	13.5%
Regions Covered	Global

Global Bi-Specific MAbS Market Trends and Strategies

• Expansion of Tumor Immunotherapy Applications
• Development of Multi-Targeted Bi-Specific Antibodies
• Growth in Hemophilia and Rare Disease Treatments
• Advancements in in Vitro and in Vivo Platforms
• Rising Collaborations Between Pharma and Biotech Firms
• Artificial Intelligence & Autonomous Intelligence
• Biotechnology, Genomics & Precision Medicine
• Digitalization, Cloud, Big Data & Cybersecurity
• Industry 4.0 & Intelligent Manufacturing
• Internet of Things (Iot), Smart Infrastructure & Connected Ecosystems

Companies Featured

• F. Hoffmann-La Roche AG
• Amgen Inc
• Johnson & Johnson
• Kyowa Kirin
• Zai Lab
• Alphamab Oncology
• Celldex Therapeutics
• Biocon
• EpimAb Biotherapeutics
• ABL Bio
• Takeda Pharmaceuticals
• Innovent Biologics
• Merck & Co Inc
• Eli Lilly Company Inc.
• AbbVie Inc
• Bayer AG
• Pfizer Inc
• Novartis AG
• GlaxoSmithKline
• AstraZeneca
• Cytiva
• Bristol Myers Squibb
• AbCellera
• BioMarin Pharmaceuticals
• Sanofi S.A.
• Novo Nordisk A/S
• Aspen Pharmacare
• Baxter International

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• Bi-Specific MAbS Market

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN07052026004107003653ID1111081639